Skip to content

UREMIC TOXIN: Utility in REnal disease of Measuring Indoxyl sulphate and p-Cresyl sulphate To predict OXidative stress, Inflammation and cliNical outcomes

A retrospective cross-sectional/longitudinal observational study looking at the concentration of uremic toxins with poor outcomes in patients with Chronic Kidney Disease Stage 1-5

Status
Completed
Phases
Unknown
Study type
Observational
Source
ANZCTR
Registry ID
ACTRN12612000760875
Acronym
Uremic Toxin
Enrollment
300
Registered
2012-07-17
Start date
2012-01-01
Completion date
Unknown
Last updated
2020-01-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Brief summary

The roles of indoxyl sulphate and p-cresyl sulphate as nephro- and cardiovascular toxins has recently gained recognition, although their true association and mechanisms behind their putative deleterious actions are yet to be investigated in human studies. The aim of this observational study is to gain a better understanding of the associations between these two protein-bound uremic toxins, IS and PCS, and Cardio Vascular Disease (CVD) and CKD progression, along with other poor outcomes seen in CKD. A secondary aim is to determine whether live kidney donors post nephrectomy have an increase concentration of these toxins and any association with morbidity in this population.

Interventions

Chronic Kidney Disease level of uremic toxins (serum analysis), CVD biomarkers (arterial stiffness by aortic pulse-wave velocity (PWV); atheroma burden by carotid intima-media thickness (cIMT) and endothelial function by flow-mediated dilation (FMD) of the brachial artery), and inflammation (serum markers) for two years. All of the above will be performed at three time points baselines, 1 year and 2 year.

Sponsors

Princess Alexandra Hospital
Lead SponsorHospital

Eligibility

Sex/Gender
All
Age
18 Years to 100 Years
Healthy volunteers
No

Inclusion criteria

Chronic Kidney Disease (CKD) (stage1-5D) >/= 18 years Able to provide informed consent

Exclusion criteria

Non CKD Unable/unwilling to give informed consent Unable/unwilling to comply with frequent follow-up Life expectancy was severely limited due to pre-existing malignancy or other disease (<6 months) Pregnancy

Outcome results

None listed

Source: ANZCTR · Data processed: Feb 4, 2026